Bold Therapeutics presented details on its GI cancer program BOLD-100 at BIO-Europe 2026, describing progress in a global randomized Phase 2 trial in colorectal, gastric, biliary tract, and pancreatic cancer settings. The company said a midway enrollment milestone triggered an interim analysis and that results showed improvements across endpoints including progression-free survival and overall survival in combination with standard of care. The company also highlighted tolerability, specifically aiming to moderate chemotherapy-induced peripheral neuropathy as treatment lines move earlier. If interim signals persist in later readouts, BOLD-100 could carve a niche by combining efficacy with neuropathy mitigation—an execution differentiator in GI oncology.